This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We read with interest the comment made by Gavriilaki et al. on our article1 about the uncertain role of ADAMTS13 antigen as a marker given the high variability and its uncertain role in thrombotic thrombocytopenic purpura (TTP). In the stroke field, ADAMTS13 activity was originally found to be reduced in the acute setting.2 Later, antigen levels were also reported to be reduced in the acute phase when compared with both healthy controls and chronic strokes.3 Correlations between antigen and activity have not been performed in a larger acute stroke cohort to our knowledge. We measured ADAMTS13 antigen in 57 patients with available serum from the first (IV tissue plasminogen activator) cohort of our original study1; we observed no correlation between ADAMTS 13 antigen and activity levels (R = 0.074, p = 0.590).
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke
Editors' note: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke
Increased von Willebrand factor in migraine
Reader response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke